LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prothena Corporation plc (''Prothena” or ''the Company'') (NASDAQ: PRTA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Prothena withheld clinical trial data demonstrating that its antibody, NEOD001, was not a clinically effective treatment for AL amyloidosis. The Company also made misleading comparisons of NEOD001’s “best response” rate against prior studies. Prothena made misleading statements about the ongoing Phase 1/2 study of NEOD001, stating that the study would create a strong foundation for late-stage Phase 2b and Phase 3 studies of the antibody, while the full Phase 1/2 data showed the antibody was not an effective treatment. When accurate information about the Company became apparent in the market, investors suffered damages.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
